Literature DB >> 2692942

Disposition of anticonvulsants in childhood.

J I Morrow1, A Richens.   

Abstract

There have been great advances in our understanding of the childhood epilepsies within recent years and at the same time there has been increasing awareness of the pharmacokinetic properties of the anticonvulsant drugs. It has been increasingly recognised that pharmacokinetic parameters of anticonvulsants are not constant, but are subject to influences by a number of physiological variables over which age is a major determinant. As changes in pharmacokinetic parameters will alter dosage requirements, dosage regimens cannot be transferred from one age group to another without the risk of underdosing or overdosing. Drug monitoring techniques are being increasingly used as a guide to correct dosing but knowledge of the limitations of monitoring is as important as knowledge of potential benefits for monitoring to be used correctly. An overview of the important pharmacokinetic properties of anticonvulsant drugs is provided, with emphasis on findings in children where such data are available.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692942     DOI: 10.2165/00003088-198900171-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  59 in total

1.  Overuse of monitoring of blood concentrations of antiepileptic drugs.

Authors:  D W Chadwick
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

2.  Pharmacokinetics of single and multiple doses of clobazam in humans.

Authors:  W Rupp; M Badian; O Christ; P Hajdú; R D Kulkarni; K Taeuber; M Uihlein; R Bender; O Vanderbeke
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 3.  Metabolism of certain commonly used barbiturates.

Authors:  R I Freudenthal; F I Carroll
Journal:  Drug Metab Rev       Date:  1973       Impact factor: 4.518

4.  Outbreak of anticonvulsant intoxication in an Australian city.

Authors:  J H Tyrer; M J Eadie; J M Sutherland; W D Hooper
Journal:  Br Med J       Date:  1970-10-31

Review 5.  Anticonvulsant drugs, behavior, and cognitive abilities.

Authors:  M Trimble
Journal:  Curr Dev Psychopharmacol       Date:  1981

6.  Brain uptake of phenytoin, phenobarbital, and diazepam.

Authors:  R E Ramsay; E J Hammond; R J Perchalski; B J Wilder
Journal:  Arch Neurol       Date:  1979-09

7.  Blood levels of diazepam after single rectal administration in infants and children.

Authors:  O Dulac; J Aicardi; E Rey; G Olive
Journal:  J Pediatr       Date:  1978-12       Impact factor: 4.406

Review 8.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

9.  Phenylethylmalonamide (PEMA). An important metabolite of primidone.

Authors:  I P Baumel; B B Gallagher; R H Mattson
Journal:  Arch Neurol       Date:  1972-07

10.  Plasma protein binding interaction between phenytoin and valproic acid in vitro.

Authors:  A Monks; S Boobis; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

View more
  3 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

Review 3.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.